SC
BMRN icon

Syon Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Syon Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,908
Closed -$520K – 595
2024
Q4 		$520K Buy
+7,908
New +$530K 0.05% 276

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Syon Capital's BMRN Position: Q1 2025 in Review

Syon Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2025, closing a stake of 7,908 shares — an estimated $520K sold.

Syon Capital first reported a position in BMRN in Q4 2024 and held it in 1 quarter. The position peaked at $520K in Q4 2024. 584 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.

  • Syon Capital reported no remaining BioMarin Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Syon Capital sold 7,908 BioMarin Pharmaceuticals shares in Q1 2025, an estimated $520K.
  • Syon Capital first reported a position in BioMarin Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Syon Capital's BioMarin Pharmaceuticals position peaked at $520K in Q4 2024.
  • 584 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.

Based on Syon Capital's 13F filing for Q1 2025, filed 15 May 2025.